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Autonomic Nervous System (ANS) func-
tion has been assessed in several muscular
dystrophies. In the last two decades it
has been recognized a significant relation-
ship between ANS and cardiac mortal-
ity (Palladino et al., 2008). Cardiovascular
ANS is frequently studied by using car-
diovascular autonomic reflex tests and
spectral analysis of heart rate in time
and frequency domain (Ewing and Clarke,
1982; van Ravenswaaij-Arts et al., 1993).
Heart rate variability (HRV) analysis,
which involves measurement and analysis
of heart rate variation, provides a quantita-
tive marker of autonomic activity and has
proved to be able to detect and measure
modification in sympathetic or vagal activ-
ity. Moreover, it can be used to estimate the
susceptibility for heart arrhythmias (Heart
rate variability, 1996a,b).
DYSTROPHINOPATHIES
Duchenne (DMD) and Becker (BMD)
muscular dystrophies are X-linked
recessive disorders due to complete or
partial loss of dystrophin protein. The
presence of persistent sinus tachycar-
dia, atrial and ventricular arrhythmias,
sweating and chills has suggested an ANS
involvement in these disorders.
Yotsukura et al. first described an
impairment of ANS in 55DMD, character-
ized by an increase in sympathetic activ-
ity and a reduction in parasympathetic
output. These abnormalities were present
early in the course of the disease, when
cardiopulmonary function was still essen-
tially normal, and became more marked
with the progression of the disorder. The
authors demonstrated also that, although
HRV tended to decrease with the progress
of clinical severity, it cannot be consid-
ered a good predictor of death in DMD
(Yotsukura et al., 1995, 1998).
ANS impairment was confirmed by
Lanza et al. (2001) and by Inoue et al.
(2009) who proposed that the mean heart
rate during night could be used as a simple
measurement for evaluation of autonomic
function and that early treatment against
tachycardia should be initiated when a
patient’s mean heart rate at night is > 71
beats/min.
The neuropathological evidence of
ANS involvement in DMD has been
shown in mdx mice, where a selective
loss of the sympathetic superior cervical
ganglion (SCG) neurons, combined with
the dystrophin-associated muscle damage,
might lead to ganglion neuron death (De
Stefano et al., 2005).
In 1997, the arrhythmic profile in
a population of 20 BMD patients was
investigated to correlate the severity of
arrhythmic events, the cardiac autonomic
balance (assessed by HRV analysis in
the time domain) and the degree of
left systolic impairment (Ducceschi et al.,
1997). In this study they observed a
cardiac autonomic imbalance character-
ized by sympathetic predominance and
an increased susceptibility to ventricular
arrhythmias, even in the absence of overt
cardiomyopathy; however, the severity of
arrhythmic profile was closely related to
the degree of left ventricular systolic dys-
function (Ducceschi et al., 1997).
In a subsequent study, 20 BMD patients
were investigated with a battery of six
cardiovascular autonomic tests and power
spectral analysis of HRV (Vita et al., 2001).
Although 11 patients revealed abnormal
findings at some cardiovascular tests, none
of them had a definite autonomic damage,
as indicated by two or more abnormal
tests. This clinical observation suggested
therefore that autonomic involvement
does not represent amajor finding in BMD
(Vita et al., 2001).
In 2006 the prognostic value of HRV
for sudden death was evaluated in a pop-
ulation of 30 BMD patients and dilated
cardiomyopathy compared with a control
group of 30 normal subjects (Ammendola
et al., 2006). An increment of sympathetic
tone in BMD was observed, characterized
by a lower HRV in the frequency and time
domains and a highermean heart rate than
in the control group. HRVwas lower in the
high arrhythmic risk BMD group than in
the remaining patients. All BMD patients
who died had lower HRV than the mini-
mum HRV recorded in the survivors and
none of them had an abnormal standard
deviation of all normal RR interval over
24 h (SDNN). SDNN is considered the
most important parameter to estimate the
adrenergic activity, being inversely related
to it. This study concluded that ANS may
have an important role in BMD and that
SDNN values <100ms may be a signif-
icant predictors of cardiac death, inde-
pendent of clinical variables (Ammendola
et al., 2006). No study has been so far
conducted in DMD/BMD carriers.
MYOTONIC DYSTROPHIES
Myotonic dystrophy (DM) is a chronic and
slowly progressive, autosomal-dominant,
multisystem disease characterized by a
wide spectrum of clinical findings and
by marked intrafamilial and interfamilial
clinical variability. There are two geneti-
cally distinct form of DM, myotonic dys-
trophy type 1 (DM1) and type 2 (DM2)
with different clinical phenotypes. The
most frequent form is DM1 and on the
basis of clinical severity the disorder is
divided into three groups: mild, classi-
cal, and congenital. DM1 is caused by
a (CTG)n expansion in the gene encod-
ing Dystrophia-Myotonica-Protein-Kinase
(DMPK), a zinc finger protein. When
transcribed into CUG-containing RNA,
mutant transcripts aggregate as nuclear
foci that sequester RNA-binding pro-
teins, resulting in a spliceopathy of down-
stream effector proteins (troponin, insulin
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receptor, etc.). DM1 may be considered as
a toxic RNA disease (Udd and Krahe, 2012;
Kumar et al., 2013).
In DM1 symptoms suggestive of ANS
involvement such as heart rhythm conduc-
tion disturbances, orthostatic hypoten-
sion, disorders of sweating, abnormal gut
movements, and dysfunction of genitouri-
nary apparatus are frequently referred
(Aminoff et al., 1985). Conduction and
heart rhythm disturbances are character-
ized by brady-arrhythmias leading to atri-
oventricular block, ectopic beats, atrial
fibrillation, flutter, and other types of
tachy-arrhythmias. We found a correla-
tion between conduction heart system
defects and (CTG)n expansion (Melacini
et al., 1995). A systematic heart func-
tion follow up should be performed
in DM1 patients periodically, even in
asymptomatic patients to prevent sudden
death.
Cardiovascular ANS is frequently stud-
ied by using cardiovascular autonomic
reflex tests and spectral analysis of heart
rate in time and frequency domain (Ewing
and Clarke, 1982; van Ravenswaaij-Arts
et al., 1993).
The cardiovascular autonomic function
test was first investigated in DM1 demon-
strating only minor signs of parasympa-
thetic dysfunction and suggested that the
symptoms referred to an autonomic dys-
function could be ascribed to target organ
abnormality rather than to ANS dysfunc-
tion (Olofsson et al., 1990; den Heijer
et al., 1991; Pierangeli et al., 1992).
In 23 DM1 patients a battery of car-
diovascular reflex tests were studied, and
in parallel nerve conduction, heart and
breathing evaluation were done. Fourteen
patients showed some alterations and one
a definite autonomic damage to the battery
of cardiovascular tests without correla-
tion to other clinical parameters including
heart abnormality, electro-neurography
or spirometry (Di Leo et al., 2004).
Subsequently, a battery of autonomic
tests was performed in 20 DM1 patients
and the same sample sympathetic and
vagal hyper/hypoactivity were observed
(Rakoèevic´-Stojanovic´ et al., 2007). The
limits of these studies are the small size
of DM1 patient cohorts and the different
clinical techniques employed.
HRV and its indices in time and fre-
quency domain may be considered as
indicators of autonomic modulation of
the heart and a possible predictor of
mortality for sudden cardiac death or
fatal arrhythmias in a series of different
heart conditions such as congestive heart
failure, ischemic heart disease or after
heart transplantation. HRV study was also
investigated in various types of muscu-
lar dystrophies, including DM1 (Palladino
et al., 2008), to predict sudden cardiac
death.
The total power and low-frequency
component (a marker of sympathetic and
vagal modulation of heart rate) and high-
frequency component (a marker of vagal
modulation of heart rate) resulted to be
lower than those in the control group
(Inoue et al., 1995).
Hardin et al. (2003) studied HRV
in 289 DM1 patients showing that the
24-h time domain parameters of SDNN
and SDANN decrease with age and with
increased (CTG)n repeat length (Hardin
et al., 2003).
Di Leo et al. (2004) found that a reduc-
tion in the supine low-frequency band
inversely correlates with disease duration
and low-frequency power during standing
and was significantly associated with pres-
ence of heart involvement (Di Leo et al.,
2004). Both 24-h time domain parame-
ters of SDNN and total power resulted
significantly lower in DM1 patients than
in healthy controls (Rakoèevic´-Stojanovic´
et al., 2007). Magrì et al. (2012) recently
studied in 43 DM1 patients the QT vari-
ability index as a marker of temporal
myocardial repolarization beyond cardiac
conduction abnormalities and power spec-
tral components. The first one resulted
higher while the second ones lower in
DM1 than normal controls (Magrì et al.,
2012).
Fregonezi et al. (2012) found influ-
ence of gender and disease on HRV
in DM1 patients and healthy individu-
als in different body positions (sitting
and supine). HRV was done during short
time periods in sitting and supine posi-
tions in addition to analyse the mag-
nitude of gender influence. They found
that males with DM1 have a different
behavior than women both in sitting and
standing position. This study is important
in several ways since it indicates a gen-




Facio Scapulo Humeral Muscular
Dystrophy (FSHD) is the third most fre-
quent form of muscular dystrophy. HRV
was evaluated in 55 FSHD patients and
evidenced the presence of autonomic
modifications, characterized by slight
increase in sympathetic activity and a
progressive decrease in parasympathetic
output, which became more evident with





(EDMD) is genetically heterogeneous
since it may be caused by a muta-
tion in the STA gene encoding emerin
(X-linked inheritance) or as AD trait
determined by mutations in the LMNA
gene encoding lamin A/C. EDMD is clin-
ically characterized by a slow progressive
muscular dystrophy, joint contractures
and prominent cardiomyopathy with car-
diac conduction abnormalities that might
cause sudden death.
Fujita et al. performed I [123] MIBG
myocardial scintigraphy in a patient with
a nonsense mutation in the STA gene.
MIBG is an analog of norepinephrine
and is stored in presynaptic terminals of
sympathetic nerves. The scintigraphy evi-
denced a diffuse and severe decrease in
accumulation of MIBG in the heart sug-
gesting an abnormality in the cardiac sym-
pathetic nerve terminals in the patient.
They suggested that the abnormality on I
[123] MIBG myocardial scintigraphy may
predict LV dysfunction in EDMD (Fujiita
et al., 2005).
MIYOSHI MUSCULAR DYSTROPHY
Miyoshi muscular dystrophy (MMD) is
caused by mutation in the gene encod-
ing the protein dysferlin. In 1994, Tomoda
et al. performed accurate autonomic stud-
ies in 2 MMD affected girls, including
laser doppler flowmetry, study of the com-
ponent analysis of the cardiographic R-
R interval and sympathetic skin response
(SSR). They demonstrated marked abnor-
malities such as sensitive vasoconstric-
tive response, a suppressed peak of low
frequency components, and an absence
of SSR, compared to healthy controls.
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Table 1 | Autonomic dysfunctions in various types of muscular dystrophies.
Type of dystrophy Severity of ANS Complication needing prevention or treatment
involvement
Duchenne muscular dystrophy (DMD) ++ Tachycardia, atrial and ventricular arrhythmia, sweating, and chills
Becker muscular dystrophy (BMD) + Lower HRV in frequency in high arrhythmic BMD, increased sympathetic tone
DM1 ++ Orthostatic hypotension, heart rhythm disturbances, abnormal gut movements,
bradi-arrhythmia leading to heart block
EDMD ++ Heart block (defibrillator)
FSHD ± Tachycardia
Miyoshi myopathy ± Abnormal sympathetic skin response and vasoconstrictive response
FCMD + + + Brain stem dysfunction, reduction of cathecolaminergic neurons in reticular formation, and
nucleus tractus solitarius
Sympathetic nerve blocking produced




Fukuyama-type congenital muscular dys-
trophy (FCMD) is an autosomal recessive
disease caused by mutation in the fukutin
gene. The study of brainstem tissue of
10 patients affected by FCMD showed a
notable reduction of the catecholaminer-
gic neurons in the reticular formation,
vagal nuclei, and nucleus tractus solitar-
ius of FCMD cases compared to controls.
The Authors suggested that neuronal dys-
function in the cardiovascular and respira-
tory centers may lead to sudden death in
FCMD (Itoh et al., 1996).
In conclusion, in agreement with
ENMC International Workshop (van
Engelen et al., 2005) our suggestion
for autonomic dysfunction in muscular
dystrophy is presented in Table 1. In par-
ticular, in DM1, cardiac problems can be
unrecognized. Since physical activities pre-
cipitate arrhythmias, we advise periodic
monitoring in DM1, dystrophinopathies,
and EDMD. A program of HRV mon-
itoring should be done before exercise
and rehabilitation in patients with overt
autonomic dysfunction.
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